Dirk Blom

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

Heart Failure, Lipid Peroxidation, Hyperlipidemia +19

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Raúl D. Santos, Dirk Blom et al. · The Lancet · 2010 · 897 citations

Homozygous Familial Hypercholesterolaemia, Oxysterol, Cardiovascular Disease +7

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Marina Cuchel, Emma A. Meagher, Hendrik du Toit Theron et al. · The Lancet · 2012 · 728 citations · Full text

Metabolic Syndrome, Lipid Disorder, Homozygous Familial Hypercholesterolaemia +7

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Narimon Honarpour, Dirk Blom et al. · The Lancet · 2014 · 720 citations

Metabolic Syndrome, Lipid Disorder, Homozygous Familial Hypercholesterolaemia +11